Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 3/20 | 0.38 |
| ▸ | CTRC | Q99895 | 3/20 | 0.38 |
| ▸ | F3 | P13726 | 5/20 | 0.38 |
| ▸ | F7 | P08709 | 3/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765875 | 0.96 | F2 (0.42) | F2NTRK1CMA1CTRCF3 | |
| SCHEMBL30765820 | 0.91 | CMA1 (0.40) | F2NTRK1CMA1CTRCF3 | |
| SCHEMBL30765583 | 0.91 | F2 (0.40) | F2NTRK1CMA1CTRCF3 | |
| SCHEMBL30765550 | 0.90 | F2 (0.38) | F2NTRK1CMA1CTRCF3 | |
| SCHEMBL30765437 | 0.89 | HDAC6 (0.41) | F2CMA1CTRCF3F7 | |
| SCHEMBL30765527 | 0.88 | NAMPT (0.44) | F2NTRK1F3F7PRSS1 | |
| SCHEMBL30765985 | 0.88 | NAMPT (0.38) | F2NTRK1F3F7PRSS1 | |
| SCHEMBL30765937 | 0.88 | F2 (0.39) | F2NTRK1CMA1CTRCF3 | |
| SCHEMBL30765489 | 0.88 | F2 (0.39) | F2NTRK1CMA1CTRCF3 | |
| SCHEMBL30765918 | 0.87 | NAMPT (0.41) | F2NTRK1F3F7PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |